Sector News

Valeant closing in on $160-per-share Salix deal: Reuters

February 20, 2015
Life sciences
There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters’ sources, serial acquirer Valeant has the lead.
 
CEO J. Michael Pearson’s company is close to inking a deal for the North Carolina drugmaker at around $160 per share, the news service reports, and an agreement could come as early as next week.
 
But a couple other pharma players may have a mind to get in the way. Word has it that Shire is working with its own advisers on a potential offer, and Endo has also reportedly come calling multiple times.
 
A bidding war could potentially sour things for Valeant, which prides itself on its discipline. It’s that restraint that last November ended a months-long hostile pursuit of Allergan), with Pearson saying he “couldn’t justify” topping the $66 billion offer that white knight Actavis put forth.
 
And Shire, for one, has plenty of cash to throw around. CEO Flemming Ornskov has said multiple times that the Dublin drugmaker is looking for deals to help it reach its $10 billion 2020 sales goal, particularly in areas his company knows well. GI, Salix’s specialty, just so happens to be one such area.
 
For some of Salix’s investors, a sale will be a win no matter who nabs the company. Shareholders have been pushing for a buyout since Salix late last year acknowledged an inventory snafu that overstated sales and sent its CFO packing. After all, those issues may have already scuttled one deal: They cost it a tie-up with Allergan while it was looking to dodge Valeant, The Wall Street Journal said in November.
 
By Carly Helfand
 

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend